...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Public health reports >Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015
【24h】

Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015

机译：医疗补助在美国，美国，2015年幼儿注意缺陷/多动障碍的药物治疗药物治疗授权政策

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives: In 2011, the American Academy of Pediatrics updated its guidelines for the diagnosis and treatment of children with attention-deficit/hyperactivity disorder (ADHD) to recommend that clinicians refer parents of preschoolers (aged 4-5) for training in behavior therapy and subsequently treat with medication if behavior therapy fails to sufficiently improve functioning. Data available from just before the release of the guidelines suggest that fewer than half of preschoolers with ADHD received behavior therapy and about half received medication. About half of those who received medication also received behavior therapy. Prior authorization policies for ADHD medication may guide physicians toward recommended behavior therapy. Characterizing existing prior authorization policies is an important step toward evaluating the impact of these policies on treatment patterns. We inventoried existing prior authorization policies and characterized policy components to inform future evaluation efforts.
机译：目标：2011年，美国儿科学院更新了其对注意力缺陷/多动障碍（ADHD）的儿童诊断和治疗的准则，建议临床医生在行为治疗中提及学龄前儿童（年龄4-5岁）的父母进行培训如果行为治疗不能充分改善功能，随后用药物治疗。在释放指南之前提供的数据表明，少于一半的学龄前儿童，ADHD接受了行为疗法和大约一半收入的药物。约有一半接受药物的人也接受了行为治疗。 ADHD药物的先前授权政策可能导致医生朝着推荐的行为治疗。特征现有事先授权政策是评估这些政策对治疗模式的影响的重要一步。我们将现有的现有授权策略和特征策略组件列入了现有的先前授权策略，以告知未来的评估努力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号